Asymmetric bioreduction of activated alkenes by a novel isolate of Achromobacter species producing enoate reductase

Research output: Contribution to journalArticleScientificpeer-review

Researchers

  • Yan Jie Liu
  • Xiao Qiong Pei
  • Hui Lin
  • Ping Gai
  • Yu Chang Liu
  • Zhong Liu Wu

Research units

  • CAS - Chengdu Institute of Biology
  • University of Chinese Academy of Sciences

Abstract

The strain Achromobacter sp. JA81, which produced enoate reductase, was applied in the asymmetric reduction of activated alkenes. The strain could catalyze the bioreduction of alkenes to form enantiopure (R)-ß-aryl- ß-cyano-propanoic acids, a precursor of (R)-?-amino butyric acids, including the pharmaceutically active enantiomer of the chiral drug (R)-baclofen with excellent enantioselectivity. It could catalyze aswell the stereoselective bioreduction of other activated alkenes such as cyclic imides, ß-nitro acrylates, and nitro-alkenes with up to >99 % ee and >99 % conversion. The draft genome sequencing of JA81 revealed six putative old yellow enzyme homologies, and the transcription of one of them, Achr-OYE3, was detected using reverse transcription polymerase chain reaction. The recombinant Escherichia coli expressing Achr-OYE3 displayed enoate reductase activity toward (Z)-3-cyano-3-phenyl-propenoic acid (2a).

Details

Original languageEnglish
Pages (from-to)635-645
Number of pages11
JournalApplied Microbiology and Biotechnology
Volume95
Issue number3
Publication statusPublished - Aug 2012
MoE publication typeA1 Journal article-refereed

    Research areas

  • Achromobacter sp., Activated alkene, Asymmetric reduction, Baclofen, Enoate reductase, Old yellow enzyme

ID: 14582377